AllSight
Companies · CRNX · Pharmaceutical Preparations · Acquisition · Sep 1, 2026

Crinetics closes Vertex’s $10B buyout, ending its public-market story

$10B acquisitionpriced in
Merger closed at the previously disclosed $85.00 cash-per-share consideration
Crinetics Pharmaceuticals, Inc. (CRNX) — what happened, in plain English, and what it means versus what the market expected.

This is a closing confirmation, not a fresh deal surprise. Vertex completed the merger on September 1, 2026, after the transaction and its $85.00-per-share cash terms had already been disclosed on July 6. The filing says the merger became effective on the Closing Date (Introductory Note). 〔0〕

Shareholders receive cash, while the equity story ends. Each eligible Crinetics share was converted into the right to receive $85.00 in cash, and holders ceased to have stockholder rights other than the right to receive that consideration (Introductory Note; Material Modification to Rights of Security Holders).

The transaction fully removes Crinetics from the public market. Vertex now owns Crinetics as a wholly owned subsidiary; Nasdaq trading was suspended, and the company requested delisting and deregistration (Changes in Control; Delisting). 〔1〕

Operational control has transferred to Vertex. Crinetics’ directors resigned, its prior officers were removed, and Charles Wagner, Prasanna Thombre and Omar White became president, treasurer and secretary of the surviving subsidiary (Changes in Officers and Directors). 〔2〕

Net read: in line and fully priced in. The filing confirms the expected completion of the announced all-cash acquisition; it adds execution certainty but does not change the disclosed price, strategic terms, or shareholder outcome.

Read the original 8-K on SEC EDGAR ↗
More from Crinetics Pharmaceuticals, Inc. (CRNX)
Aug 19, 2026Crinetics supplements Vertex merger proxy after lawsuits, leaves $85 offer unchangedAug 14, 2026Vertex’s Crinetics deal clears antitrust—only the shareholder vote remainsAll CRNX filings, decoded →
Related companies in Pharmaceutical Preparations
Latest across the market
ACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeIIPRIIPR loan increase funds Alewife buildout, but locks in 14% debtGLUEMonte Rosa GFORCE-1 results clear safety bar, but ASCVD Phase 2 moves to 2027SMASmartStop dividend holds at $1.60 annualized as October payout repeats patternHBNCHorizon Bancorp schedules Q3 earnings, offering no fresh business readBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact